Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?  

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice